Analyst firms · Goldman Sachs · APLS
Goldman Sachs APLS price target and rating history
Apellis Pharmaceuticals Inc. (APLS) · Health Care
Goldman Sachs rates Apellis Pharmaceuticals Inc. (APLS) Sell with a $18 price target, as of its latest action on Sep 26, 2025. It has published 4 rating actions on APLS since March 2022, including 0 upgrades and 2 downgrades. Across 3 firms with a APLS price target in the last 12 months, the median target is $28.
- Current rating
- Sell
- Price target
- $18
- Median target, all firms
- $28
- Actions on APLS
- 4
Goldman Sachs price target on APLS
Every Goldman Sachs rating on APLS
- Sep 26, 2025
- Dec 17, 2024
- Nov 9, 2023
- Mar 7, 2022
How other firms rate APLS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Roth Capital | Buy | $31 | Mar 13, 2026 |
| Barclays | Equal Weight | $24 | Jan 28, 2026 |
| BofA Securities | Buy | $28 | Jan 21, 2026 |
Questions about Goldman Sachs and APLS
- What is Goldman Sachs's price target for APLS?
- Goldman Sachs's latest stated price target for Apellis Pharmaceuticals Inc. (APLS) is $18, from its action on Sep 26, 2025.
- What is Goldman Sachs's rating on APLS?
- Goldman Sachs rates APLS Sell, a bearish rating, as of Sep 26, 2025.
- When did Goldman Sachs last change its view on APLS?
- On Sep 26, 2025, Goldman Sachs downgrades to Sell from Neutral, price target $18.
- How does Goldman Sachs's APLS target compare with other analysts?
- Across 3 firms with a APLS price target in the last 12 months, the median target is $28.
More APLS rating histories
All Goldman Sachs ratingsAPLS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.